ESG
at Nautilus Pharma

ESG
at Nautilus Pharma

Our Approach
Nautilus Pharma manufactures innovative products that benefit people and communities while considering the environmental impacts. We integrate Sustainable Development Goals (SDGs) into our decision-making process for the turn-key solutions we offer our customers. This approach ensures we achieve SDG targets whilst mitigating negative impacts.
Our SDG-Guided Positive Impacts
We recognise that SDGs drive corporate action and reporting, with transparency becoming a new business paradigm. We view this as an opportunity to elevate our sustainability reporting and demonstrate our business impact on global priorities. We utilise guidance from the Global Reporting Initiative (GRI) and UN Global Compact to improve our SDG reporting and performance.

Our Practical Considerations
We understand that while businesses can positively impact people and the planet, we need not contribute to all SDGs. Following GRI UN Global Compact guidance, we consult our stakeholders to select relevant SDGs that align with our business operations. We ensure our corporate contributions to SDGs complement, rather than replace, government services. We focus our corporate social investment (CSI) on projects that support government efforts within our means.
Given the vast needs, we concentrate our contributions within our zone of influence. This includes the geographic area from which we draw our labour and the areas affected by our potential operational impacts, such as downstream effects on water bodies or air pollution dispersion zones.